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Summary
Picolinic acid, a catabolite of L-tryptophan, activates the transcription of the inducible nitric
oxide synthase gene (iNOS) in IFN-y-treated murine macrophages. We performed functional
studies on the 5' flanking region of the iNOS gene linked to a CAT reporter gene to identify
the cis-acting element(s) responsible for the activation ofiNOS transcription by picolinic acid.
Transient transfection assays showed that the full-length iNOS promoter in the murine mac-
rophage cell line ANA-1 was activated by the synergistic interaction between IFN-'Y and pi-
colinic acid. Deletion or mutation of the iNOS promoter region from -227 to -209, con-
taining a sequence homology to a hypoxia-responsive enhancer (iNOS-HRE), decreased
picolinic acid- but not LPS-induced CAT activity by more than 70%. Functional studies using
a tk promoter-CAT reporter gene plasmid demonstrated that the iNOS-HRE was sufficient to
confer inducibility by picolinic acid but not by IFN-y or LPS. Electrophoretic mobility shift
assays confirmed that picolinic acid alone induced a specific binding activity to the iNOS-
HRB. Furthermore, we found that the iNOS-HRE activity was inducible by hypoxia and that
hypoxia in combination with IFN-y activated the iNOS promoter in transient transfection as-
says and induced iNOS transcription and mRNA expression. These data establish that the
iNOS-HRE is a novel regulatory element of the iNOS promoter activity in murine macro-
phages and provide the first evidence that iNOS is a hypoxia-inducible gene.
itric oxide (NO) is a pleiotropic molecule involved in
neurotransmission, vascular homeostasis and effector
functions of murine macrophages (1-3) . NO is generated
during the oxidation of L-arginine to L-citrulline by at least
three different isoforms of the enzyme nitric oxide synthase
(NOS) . Neuronal and endothelial NOSs are constitutively
expressed and their activity is dependent on the levels of
Ca2+ and calmodulin. Macrophages contain a transcription-
ally inducible isoform of NOS (iNOS) (4, 5), whose activ-
ity is independent of elevated Ca21 or exogenous calmodu-
lin (6). Maximal expression of iNOS mRNA in murine
macrophages is achieved by stimulation with IFN-y plus a
second signal, such as bacterial lipopolysaccharide (LPS) (4,
'Abbreviations used in this paper: CAT, chloramphenicol acetyltransferase;
DTT, dithiothreitol; EMSA, electrophoretic mobility shift assay; Epo,
erythropoietin; HIF-1, hypoxia inducible factor-1 ; HR-E, hypoxia-re-
sponsive element; iNOS, inducible nitric oxide synthase; IRF-E, inter-
feron regulatory factor binding site; NO, nitric oxide; NOS, nitric oxide
synthase.
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5) . A 1 .6-kb fragment of the 5'-flanking region of the
mouse iNOS gene is sufficient to confer inducibility by
IFN-y plus LPS (7, 8). Additionally, the consensus se-
quences for the binding of interferon regulatory factor-1
(IRF-1) (9, 10) and NF-KB (11) of the iNOS promoter are
required for activation of transcription by IFN-y and LPS,
respectively. No other regulatory elements important for
the control of iNOS expression have been identified as yet.
The diversity of the pathological conditions in which
macrophage NO is produced may be based on the exist-
ence of several signals inducing iNOS and implies the need
for multiple regulatory elements to control its transcription
(12). In an attempt to identify additional elements regulat-
ing iNOS expression, we studied the response of macro-
phages to activating agents structurally and biologically dif-
ferent from LPS. Picolinic acid is an end catabolite of
L-tryptophan, whose metabolism is initiated by two induc-
ible enzymes, tryptophan dioxygenase in the liver and in-
doleamine 2,3-dioxygenase in extra-hepatic tissue, that dif-
fer in the response to extracellular stimulation (13-15) . The
degradation ofL-tryptophan occurs in vitro and in vivo, in
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of the biological effects of IFN-y (17, 18). Elevated levels
of tryptophan metabolites, such as kynurenine and quino-
linic acid, have been detected in vivo in cerebrospinal fluid
in pathological conditions (19, 20) as well as in cancer pa-
tients treated with IL-2 (21). Picolinic acid has been de-
tected in body fluids (22, 23), and can activate munne mac-
rophages in vivo (24-26). However, the cellular source of
picolinic acid has not been defined yet and the pathophysi-
ological role of picolinic acid remains to be fully determined.
Picolinic acid is a potent costimulatory agent for the induc-
tion of tumoricidal activity in mouse peritoneal macro-
phages (27) as well as in the mouse macrophage cell lines
ANA-1 and GG2EE (28, 29), the latter derived from the
LPS-hyporesponsive C3H/HeJ strain of mouse. We re-
cently demonstrated that picolinic acid is a costimulus with
IFN-y for the induction ofNO production (30) and iNOS
mRNA transcription in murine macrophages (31) . These
observations suggest a possible connection between tryp-
tophan and arginine metabolism, two oxidative amino acid
metabolic pathways leading to biologically active mole-
cules, and indicate that amino acid catabolites may play a
role in the transcriptional control of gene expression in
murine macrophages. However, the DNA regulatory ele-
ment(s) required for picolinic acid-induced transcription of
the iNOS gene are not known.
We have performed functional studies on the 5'-flanking
region of the iNOS gene to characterize the cis-acting ele-
ments) responsible for the activation of iNOS transcription
by picolinic acid in ANA-1 murine macrophages. We have
found that a 19-base pairs (bp) region of the iNOS pro-
moter, containing a sequence homology to a hypoxia-
inducible enhancer, is required for picolinic acid-, but not
for LPS-induced, activation of iNOS promoter. The hy-
poxia-responsive element (HRE) present in the iNOS pro-
moter responds also to hypoxia that in combination with
IFN-y is a stimulus forthe induction ofiNOS transcription
and mRNA expression. These data demonstrate the exist-
ence of a novel regulatory element of the iNOS promoter,
that is active in the control of iNOS transcription in mu-
rine macrophages.
Materials and Methods
Cells.
￿
Themouse macrophage cell line ANA-1 was established
by infecting fresh bone marrow-derived cellsfrom C57BL/6 mice
with theJ2 (v-raf1v-myc) recombinant retrovirus (32, 33). ANA-1
macrophages were cultured in DMEM (BioWhittaker, Inc.,
Walkersville, MD) supplemented with 10% heat-inactivated FCS
(HyClone Laboratories, Logan, UT), 2 MM L-glutamine, 100
U/ml of penicillin, and 100 [ .g/ml of streptomycin (GIBCO
BRL, Gaithersburg, MD) (complete medium). Cells were main-
tained at 37°C in a humidified incubator containing 20% 02, 5%
CO, in air (referred to as normoxic conditions). In some experi-
ments cells were cultured under hypoxic conditions in a modular
incubatorflushed with a mixture of 1% 02, 5% C02, and 94% N2
at 37°C in ahumidified atmosphere.
Reagents. Mouse rIFN-y (sp. act. %107 U/mg) was pur-
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chased from GIBCO BRL. LPS (from E. coli serotype 0111:134)
was purchased from Sigma Chemical Company (St. Louis, MO).
Picolinic acid was purchased from Sigma (purity -99%) and was
prepared as previously described (30). The content of endotoxin
in all the reagents was below the detection limit of 6 pg/ml, as
determined by assay with a chromogenic Limulus amebocyte ly-
sate test (Whittaker Bioproducts) .
Plasmids.
￿
The 1,749-bp fragment ofthe 5'-flanking region of
the murine iNOS gene inserted into pCAT-Basic (Promega Corp.,
Madison, WI) upstream of the promoterless chloramphenicol
acetyltransferase (CAT) gene (p1-iNOS-CAT) was kindly pro-
videdby Q. Xie andC. Nathan (Comell University Medical Col-
lege, NY). Deletion mutants were obtained by digesting pl-iNOS-
CAT with uniquely cleaving restriction enzymes and religating
the linearized plasmid. Alternatively, oligonucleotide primersbear-
ing a suitable restriction site at the 5' ends were synthesized in or-
derto obtain the desired deletion or mutation; the PCRfragments
were subsequently digested and inserted into linearized pl-iNOS-
CAT plasmids. pBLCAT2 plasmid, containing the CAT reporter
gene under the control of a HSV tk promoter fragment spanning
from -105 to +51, was used for functional studies in the context
ofa heterologous promoter. Three tandem copies ofthe double-
strand oligonucleotide depicted in Fig. 3 A were subdoned in the
HindIII/BamHI sites of pBLCAT2, 5' upstream of the HSV-tk
promoter. The constructs were sequenced using Sequenase ver-
sion 2.0 (United States Biochemical Corp ., Cleveland, OH).
Transient Transfection of ANA-1 and CAT Assay.
￿
ANA-1
macrophages were transfected by a modification of the DEAE-
dextran method (34) . After cells were washed twice with serum-
free DMEM, 10 wg ofplasmid DNA was addedto 107 cells in 1 ml
of DMEM without serum prewarmed to 37°C and containing
250 Wg/ml of DEAE-dextran and 50 mM Tris-HCI (pH 7.5).
The cells were incubated at 37°C for 1 h followed by a 2-min
shock with 10% DMSO at room temperature. The cells were
washed, plated in 6-well plates at 1 X 106/ml in 5 ml of complete
medium and incubated at 37°C in 5% CO,. 24 hlater, the appro-
priate stimulus was added to each well and the cells were incu-
bated for additional 18 h. The cells were then washed, resus-
pended in 0.25 M Tris-HCI (pH 7.5) and subjected to three
cycles of rapidfreezing andthawing. The lysates were centrifuged
(11, 000g for 10 min), the supernatants were heated at 65°C for
10 min to inactivate CAT inhibitors andassayed forCAT activity
by TLC method (35). Protein content was determined as de-
scribed by Bradford, using the Bio-Rad Protein Assay (36) (Bio-
RadLabs., Richmond, CA). To control fordifferences in the up-
take of transfected DNA, cells were cotransfected with 5 jig of
pGL2 plasmid (pGL2 control; Promega), which contains the In-
ciferase reporter gene under control of SV40 promoter and en-
hancer. Cell lysates were then assayed for luciferase activity.
Preparation ofNuclear Extracts.
￿
Cells were incubated with appro-
priate stimuli, washed twice with cold Dulbecco's phosphate-
buffered saline (PBS) and pelleted by centrifugation at 1,200 rpm
for 5 min at 4°C. Nuclear extracts were prepared by modification
ofa standard protocol (37) as described (38), with buffers Aand C
containing 2 mM dithiothreitol (DTT), 0.4 mM phenylmethyl-
sulfonyl fluoride, 1 mM sodium vanadate, and 2 wg/ml each of
leupeptin, aprotinin and pepstatin. The cell pellet was washed
with 5 packed cell volume of buffer A (10 mM Tris-HCI, pH
7.5, 1.5 MM MgCl2, 10 mM KCI), resuspended in 4 packed cell
volume ofbuffer A, and then incubated on ice for 10 min. The
cell suspension was homogenized with a glass Dounce homoge-
nizer using a type B pestle. The nuclei were pelleted by centrifu-
gation at 2,000 rpm for 5 min at 4°C and resuspended in 3 packed
Activation ofiNOS Promoter by Picolinic Acid or Hypoxianuclear volume ofbuffer C (0.42 M KCI, 20 mM Tris-HCI, pH
7.5, 20% glycerol, 1 .5 mM MgCl2). The suspension was mixed
on a rotor at 4°C for 30 min and nuclear debris was pelleted by
centrifugation for 30 min at 13,000 rpm. The supernatant was di-
alyzed against two changes of buffer -D (25 mM Tris-HCI, pH
7.5, 20% glycerol, 0.2 mM EDTA, 0.1 M KCI). Dialysate was
clarified by centrifugation at 15,000 rpm for 10 min at 4°C, and
aliquots were frozen and stored at -70°C for subsequent analysis
ofDNA binding proteins.
Electrophoretic Mobility Shift Assay (EMSA).
￿
Probes were gen-
erated either by 5'-end labeling of the double strand oligonucle-
otide with ['y32P]ATP (Amersham Corp., Arlington Heights, IL)
and T4 polynucleotide kinase (GIBCO BRL) or by Klenow frag-
ment of DNA polymerase and [a32P]dCTP. Binding reaction
was carried out in buffer D containing 5 l.tg of nuclear extract and
0.4 ltg of denatured calf thymus DNA on ice. After incubation
for 5 min, probe (1 X 104 cpm; 0.1-0.2 ng) was added and the
incubation was continued for an additional 15 min, after which
the reaction mixtures were loaded onto 5% nondenaturing poly-
acrylamide gel. Electrophoresis was performed at 180 V in 0.3X
TBE (1 X TBE is 89 mM Tris-HCl, 89 mM boric acid, and 5
mM EDTA) at 4°C. Gels were vacuum dried and autoradiographed
with intensifying screen at -70°C. Competitor DNAs were in-
cubated with nuclear extracts for 5 min before addition oflabeled
probe.
Northern Blot Analysis.
￿
ANA-1 macrophages were cultured at
1 X 106 cells/ml in 100-mm tissue culture plates and treated with
appropriate reagents as detailed in Results. Total cellular RNA
was harvested after 18 h ofincubation and processed as previously
described (31). Briefly, cells were solubilized with guanidine iso-
thiocyanate, and the total cellular RNA was purified by centrifu-
gation through a cushion of cesium chloride. 20 Wg ofRNA were
size fractionated in a 1 .2% agarose gel, blotted onto a Nytran
membrane (Schleicher & Schuell, Keene, NH), and incubated
overnight at 42°C in Hybrisol I hybridization solution (Oncor
Inc., Gaithersburg, MD). The cDNA probe that was specific for
mouse macrophage NOS (39) was radiolabeled with [32P]dCTP
(Amersham Corp.) by using a random priming kit (Boehringer
Mannheim Corp ., Indianapolis, IN). The blot was hybridized
with the radiolabeled probe (1 X 106 cpm/ml) during an over-
night incubation, washed, and autoradiographed at -70°C on
XAR-5 film (Eastman Kodak Co., San Diego, CA) with the use
of Lightning Plus intensifying screens (DuPont NEN, Wilming-
ton, DE). Equal loading of RNA was assessed by ethidium bro-
mide staining of28S and 18S rRNA.
Nuclear Run-on Experiment.
￿
Nuclei were isolated as previously
described (31) from 2.5 X 10' ANA-1 cells treated as indicated
for 12 h. Thawed nuclei were gently mixed with 150 pd 2X tran-
scription mix (1X = 100 mM Sucrose, 10% glycerol, 10 mM
Tris-HCI, pH 8.0, 2.5 MM MgC12, 2.5 mM DTT, 0.5 mM each
of ATP, CTP, and GTP) and incubated with 100 LtCi of
[32p]UTP (800 Ci/mmol; Amersham Corp.) at 30°C for 30 min.
20 pd of 100 mM CaCl2 and 20 U of RNase-free DNase I were
added and incubated 10 min at 30°C with gentle mixing every 2
min. The nuclei were then lysedwith 1 ml Trizol (GIBCO BRL)
and the RNA was isolated according to the manufacturer's pro-
cedure. Approximately, 2 X 106 cpm of RNA were used in hy-
bridization for 48 h with 2.5 1.Lg of each slot-blotted denatured
plasmid (pGEM-3Z vector alone, vector containing the 3.9-kb
cDNA insert of macrophage iNOS (39), and vector containing a
chicken [3-actin cDNA insert). Filters were washed three times
for 10 min at room temperature with 2X SSC and 0.1% SDS and
two times for 20 min at 60°C with 0 .2X SSC and 0.1% SDS. Fil-
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ters were then autoradiographed as for the Northern blot expe-
riment.
Results
Identification of a Putative Picolinic Acid-responsive Region in
the iNOS Promoter. To characterize the regulatory element(s)
ofthe iNOS promoter responsive to picolinic acid, ANA-1
macrophages were transiently transfected with plasmids
containing the full-length or deletion mutants of the 5'-
flanking region of the iNOS gene linked to the CAT re-
porter gene. The expression of the CAT gene was mea-
sured after stimulation ofthe cells with medium, IFN-y (100
U/ml) or picolinic acid (4 mM) alone or in combination.
The CAT expression following stimulation of the cells
with IFN-y plus LPS (10 ng/ml) was included as a positive
control (7, 8). As shown in Fig. 1, ANA-1 cells transfected
with the full-length construct (plasmid pl) expressed little
or no CAT activity either constitutively or after treatment
with IFN-y alone. Picolinic acid alone induced low but
appreciable levels of CAT activity. However, high levels of
transcriptional activation of iNOS promoter were induced
by the synergistic interaction between IFN-y and picolinic
acid, and were consistently observed in at least eight inde-
pendent transfection experiments. IFN-y plus LPS induced
levels of iNOS promoter activity similar to those induced
by IFN-y plus picolinic acid. Deletion of the region from
-1588 to -721 (plasmid p3), that contains an IFN-y-
responsive region at position -923 to - 913, inhibited the
synergistic interaction of IFN-y with either picolinic acid
or LPS. The CAT activity induced by picolinic acid alone
or in combination with IFN-y was decreased by 64% and
82%, respectively, relative to that observed with the full-
length iNOS promoter. In addition, deletion of the region
from -1029 to -721 (Espl to Smal site) also abrogated the
synergistic induction of CAT expression by IFN-y plus pi-
colinic acid (data not shown). These results demonstrated
that the fragment - 1588 to -721 is essential to achieve
synergistic activation of iNOS promoter by IFN-y plus pi-
colinic acid. Deletion of the region from -721 to -43
(plasmid p173) abolished CAT activity expressed either
constitutively or afterstimulation, suggesting that a putative
element responsive to picolinic acid was present in this
fragment.
The above results indicated that maximal activation of
iNOS promoter required stimulation with IFN-y plus pi-
colinic acid. To identify the regulatory sequence(s) targeted
by picolinic acid in the synergistic interaction with IFN-y
for the activation of iNOS transcription, we constructed
mutants of the iNOS promoter in which the region con-
taining IFN-y-responsive elements (from -1588 to -721)
was conserved and the fragment from -721 to -43 was
progressively deleted. As shown in Fig. 1, deletion of the
region from -721 to -410 (plasmid p162) did not inhibit
CAT expression induced by either IFN-y plus picolinic
acid or IFN-y plus LPS. In contrast, deletion of the region
from -410 to -201 (plasmid p167) strongly reduced CAT
activity induced by picolinic acid alone or in combinationFigure 1.
￿
Identification ofa picolinic acid responsive region ofiNOS promoter. ANA-1 macrophages were transfected with the indicated CAT-con-
structs as described in Materials and Methods . 24 h later, cells were treated with medium, murine rIFN-y (100 U/nd) or picolinic acid (4 mM) alone or
in combination, or IFN-y plus lipopolysaccharide (10 ng/ml) for an additional 18 h andCAT activity was assayed by TLC . The regions containing the
element(s) responsive to IFN-y and LPS, previously described in other experimental systems, are indicated in plasmid p1 . Results are expressed as relative
CAT activity, obtained by dividing CAT activity (% acetylation) by relative light units for luciferase, and are from one representative experiment of at
least four performed.
with IFN-y by 73 and 62%, respectively, without changing
significantly the levels ofCAT expression induced by IFN- 'y
plus LPS . Furthermore, deletion of only 127 by (from
-328 to -201, plasmid p201) from the full-length iNOS
promoter, caused a reduction greater than 70% of IFN-y
plus picolinic acid-induced CAT expression, but did not
affect the response to IFN-y plus LPS . These results dem-
onstrate the existence ofa novel regulatory region (-328 to
-201) required for the synergistic activation of the iNOS
promoter in response to picolinic acid but not to LPS .
Functional Requirement ofa Putative Picolinic Acid-responsive
Element in the Activation ofiNOS Promoter by IFN-y Plus Pi-
colinic Acid. Comparison ofthe sequence ofthe iNOS pro-
moter region from -328 to -201 with the sequences re-
ported in the GertBank was instrumental in pinpointing the
putative element responsive to picolinic acid . We identified
at position - 226 to -212 of the iNOS promoter a se-
quence of 14 nucleotides identical to that present in the
HR-E, originally described in the 3` flanking region of the
erythropoietin (Epo) gene, and comprising the consensus
sequence for the binding of the hypoxia inducible factor-1
(HIF-1) transcription factor (Fig. 2 A) (38) . To test whether
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the picolinic acid-responsive element mapped in the region
ofhomology with the HRE (referred to hereafter as iNOS-
HRE) we transfected ANA-1 macrophages with two iNOS
promoter-CAT reporter gene plasmids either deleted of 19
by encompassing the putative binding site of HIF-1 (-227
to -209, plasmid p220) or mutated in two bases required
for HIF-1 binding to DNA (-223 -222, plasmid p209) .
With either plasmid we observed a reduction of-70% rel-
ative to the wild-type iNOS promoter (plasmid pl) in the
expression ofCAT reporter gene induced by IFN-y plus
picolinic acid (Fig . 2 B) . A reduction ranging from 65 to
80% was consistently observed in four independent experi-
ments . The activation of iNOS promoter by treatment
with picolinic acid alone was also decreased by 90% with
both plasmids . In contrast, CAT activity induced by IFN-y
plus LPS was not significantly affected . These data demon-
strated that the iNOS-HRE is a functional regulatory ele-
ment of the iNOS promoter required for the response to
picolinic acid but not to LPS .
iNOS-HRE Confers Picolinic Acid-inducibility in the Con-
text ofa Heterologous Promoter. We then investigated the
functional activity of the iNOS-HRE in ANA-1 macro-Figure 2.
￿
A sequence homology to a hypoxia responsive element is required for induction ofiNOS promoter activity by IFN-y plus PA . (A) The se-
quence homology between iNOS promoter and erythropoietin (Epo) gene is shown in uppercase . The putative binding site ofHIF-1 is underlined . (B) .
ANA-1 macrophages were treated as described in Fig. 1 . In plasmid p220, the sequence indicated in (A) was deleted . In plasmid p209 a 2-bp mutation
(5'-TATTTGCT-3', underlined) was created at position -223 -222 internal to the putative binding site for HIF-1 . Results are expressed as in Fig . 1
and are from one representative experiment ofat least four performed .
phages and its responsiveness to picolinic acid alone . We
subcloned three tandem copies of the iNOS-HRE (from
-231 to -211), either wild type (pBL-iNOS .WT) or mu-
tated at the putative site of HIF-1 binding (pBL-iNOS.Mu)
(38) (Fig . 3 A), into the pBL-CAT2 plasmid that contains a
HSV tk promoter linked to the CAT reporter gene . These
constructs were trans£ected into ANA-1 macrophages to
determine the enhancer activity of the iNOS-HRE on the
expression of the CAT gene driven by the minimal tk pro-
moter . The pBL-iNOS.WT construct was constitutively
expressed at levels ^ "10-fold higher than the parental vec-
tor, and this value was taken as a reference to assess the ef-
fects of cell stimulation . Stimulation with picolinic acid
alone caused a major increase in CAT activity of 4.7-fold
over that of untreated cells, whereas IFN-y or LPS alone
were not effective (Fig. 3 B) . Similar results were obtained
in five independent experiments . In contrast, the expres-
sion of the pBL-iNOS.Mu plasmid was decreased more
than 10-fold, relative to that of the pBL-iNOS.WT in un-
treated cells, and was no longer inducible by picolinic acid .
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These results demonstrate that the iNOS-HRE is active in
driving transcription of a heterologous promoter in murine
macrophages and is sufficient to confer inducibility by pi-
colinic acid.
Picolinic Acid Induces DNA-binding Activity to the iNOS-
HRE . To establish whether picolinic acid inducedDNA-
binding activity to the iNOS-HRE, we performed EMSA
with nuclear extracts prepared from ANA-1 macrophages
either unstimulated or treated with picolinic acid alone and
with a radiolabeled oligonucleotide of 19 by (depicted in
Table 1, AB.2) encompassing the iNOS-HRE . ANA-1 mac-
rophages cultured in medium expressed a constitutive bind-
ing activity (Fig. 4) . Treatment with picolinic acid increased
the constitutive binding and caused the appearance of an in-
ducible complex . Competition experiments demonstrated
that the constitutive as well as the inducible binding com-
plexes were specifically inhibited by excess unlabeled probe
(AB.2), but not by an unrelated probe (AB.1) . Because
mutation of the HIF-1-binding site of the iNOS-HRE
abolished its functional activity in transient transfection as-B
AB.2 (iNOS,
-230 to -212)
Mu-AB.2
Epo
AB .1
pBLINOS.WT
pBLiNOS .Mu
MEDIUM
IFN
UPS
PA
5'-AGTGACTACGTGCTGCCTAGG-3'
5'-AGTGACTAAAAGCTGCCTAGG-3'
Table 1 .
￿
Oligonucleotide Probe Used in EMSA
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says (see Fig . 3 B), we tested whether the same mutation al-
tered the ability of the probe to compete for the binding.
As shown in Fig. 4, a probe mutated in three bases within
the putative HIF-1-binding site (Table 1, Mu.AB2) did
not compete for the picolinic acid-inducible binding com-
plex, suggesting that the integrity of the HIF-1-binding
site was required for the binding activity. In addition, the
formation ofthe constitutive or picolinic acid-inducible bind-
ing complexes was competed for by an 18-bp probe con-
taining the canonical HIF-1-binding site of Epo (Fig . 4),
that differs from the AB.2 probe in five flanking bases (Ta-
ble 1) (38) . These results indicate that a specific DNA-
binding factor, similar or closely related to HIF-1, is in-
duced by picolinic acid in ANA-1 macrophages and binds
to the iNOS-HRE .
Hypoxia Activates iNOS-HRE and iNOS Promoter in Mu-
rine Macrophages .
￿
Sequences similar to the iNOS-HRE drive
5'-GTGACTACGTGCTGCCTAG-3'
5'-GTGACTAAAAGCTGCCTAG-3'
5'-GCCCTACGTGCTGCCTCA-3'
5'-TGAGTCCCAGTTTTGAAGTG-3'
Bold characters indicate the consensus sequence for the binding of
HIF-1 ; the mutated bases are underlined . Epo probe is from the 3'
flanking region ofthe human Epo gene (from +3454 to +3471) (38) .
AB . 1 is from an unrelated sequence of the iNOS promoter.
OPBUNOS.wr
OpBUNOS.Mu
4 5
Figure 4 .
￿
Picolinic acid induces a DNA-binding activity to the iNOS-
HRE . Nuclear extracts from ANA-1 macrophages treated with medium
or picolinic acid for 12 h were incubated with AB.2 probe, in the absence
ofcompetitor (0) or in the presence of 100-fold molar excess ofthe unla-
beled AB .2, Mu-AB.2, AB .1, or Epo competitor oligonucleotides (de-
scribed in Table 1) and analyzed byEMSA . Competitor DNAs were in-
cubated with nuclear extracts for 5 min before addition oflabeled probe.
Binding activities are labeled as follows : C, constitutive ; I, induced ; Free,
free labeled probe .
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Figure 3 . iNOS-HRE confers inducibility by pi-
colinic acid in ANA-1 murine macrophages . (A) Se-
quence of the oligomers containing the iNOS-HRE
from the mouse iNOS promoter that were subcloned
in the pBLCAT2 vector as described in Materials and
Methods. Bold type indicates the putative binding site
ofHIF-1, with the mutation underlined . (B) 24 h after
the transfection with the indicated constructs, ANA-1
macrophages were treated with medium, IFN-y (100
U/ml), LPS (10 ng/ml), picolinic acid (4 mM) for ad-
ditional 24 h and CAT activity was assayed. Results are
presented as fold increase ofCAT activity (% acetyla-
tion/luciferase) relative to that expressed by pBL-
iNOS.WT in untreated cells (arbitrarily considered to
be equal to 1) after normalization for the expression of
the parental vector, and are from one representative
experiment .hypoxia-inducible transcriptional activation ofreporter genes
in other cell types (40, 41), raising the possibility that hyp-
oxia was also a stimulus for iNOS-HRE activity in macro-
phages . We tested the response of the plasmids pBL-
iNOS.WT and pBL-iNOS-Mu transfected in ANA-1
macrophages to normoxic (20% OZ) or hypoxic (1% OZ)
conditions . We found that hypoxia induced the expression
ofpBL-iNOS.WT (2.7-fold), relative to control cells cul-
tured under normoxic conditions (Fig. 5 A) . In contrast, no
induction of pBL-iNOS.Mu by hypoxia was observed .
These data demonstrate that hypoxia is a stimulus for
iNOS-HRE activity in murine macrophages . To establish
whether hypoxia induced iNOS promoter activity, ANA-1
macrophages were transiently transfected with plasmid p1,
containing the full-length 5'-flanking region of the iNOS
gene . As shown in Fig . 5 B, hypoxia alone did not induce
appreciable increase of CAT activity above the levels ex-
pressed by cells treated with IFN-y alone . However, a sig-
A
s
NORMOXIA
HYPO%IA
P1
P209
P220
0.5 1 1 .5 2 2.5 3
Fold increase
®Medium
FN
OHypoxia
MIFN+Hypoxia
0 .2 0.4 0 .6 0.8 1
Relative CAT activity
Figure 5 .
￿
Hypoxia induces iNOS-HRE and iNOS promoter activity .
(A) 24 h after the transfection with the indicated constructs, described in
the legend to Fig . 3 A, ANA-1 macrophages were cultured in medium
either under normoxic (20% 02) or under hypoxic conditions (1% OZ )
for additional 24 h. Results are presented as fold increase ofCAT activity
(% acetylation/luciferase) relative to that expressed by cells cultured under
normoxic conditions transfected with pBL-iNOS.WT (arbitrarily consid-
ered to be equal to 1) after normalization for the expression of the paren-
tal vector, and are from one representative experiment. (B) ANA-1 mac-
rophages were transfected with the indicated constructs, described in the
legend to Fig . 2 . 24 h later the cells were treated with medium or IFN-y
(100 U/ml) and cultured under either normoxic (20% OZ ) or hypoxic
(1% OZ ) conditions, as described, for an additional 24 h . Results are ex-
pressed as in Fig. 1 and are from one representative experiment of at least
three performed.
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nificant induction of CAT expression was observed after
treatment with IFN-y under hypoxic conditions, indicat-
ing that hypoxia is a costimulus for the induction ofiNOS
promoter activity . To investigate whether the iNOS-HRE
was responsible for the activation of iNOS promoter by
hypoxia, we tested the activity ofplasmid p220 and plasmid
p209, deleted or mutated in the iNOS-HRE, respectively .
With both plasmids we observed a decrease of-80% rela-
tive to the wild-type iNOS promoter in the induction of
CAT activity following stimulation with IFN-y under
hypoxic conditions (Fig . 5 B) . These data establish that the
iNOS-HRE is required for the induction of iNOS pro-
moter activity by hypoxia .
Hypoxia Induces iNOS mRNA Expression and iNOS Tran-
scription . The inducibility ofiNOS promoter by hypoxia
raised the possibility that the expression of the endogenous
iNOS gene was sensitive to a decrease in oxygen levels . To
address this issue, ANA-1 macrophages were incubated un-
der normoxic or hypoxic conditions, in medium alone or
medium containing IFN-y and tested for iNOS mRNA
expression (Fig . 6 A) and iNOS transcription (Fig . 6 B) .
The iNOS gene was not constitutively expressed either un-
der normoxic or hypoxic conditions, and IFN-y, under
normal oxygen tension, induced very low levels ofiNOS
mRNA expression . In contrast, under hypoxic conditions,
IFN-y induced a major increase ofiNOS mRNA expres-
sion and iNOS transcription, providing the first demon-
stration that iNOS is inducible by a decrease in oxygen
tension .
Discussion
We have identified a novel regulatory element (iNOS-
HRE, from -227 to -209) that is required to achieve full
expression ofiNOS promoter activity in response to IFN-y
Figure 6 .
￿
Hypoxia synergizes with IFN-y in the induction of iNOS
mRNA expression and iNOS transcription . (A) Northern blot . ANA-1
macrophages were treated with medium or IFN-y (100 U/ml) and incu-
bated for 18 h either in 20% OZ or 1% O Z , as described in Fig . 5 . Total
cellularRNA was examined for iNOS mRNA expression as described in
Materials and Methods . EqualRNA loading was confirmed by ethidium
bromide staining and monitoring of28S and 18S rRNA (data not shown) .
Data shown are from one representative experiment of three performed .
(B) Nuclear run-on . ANA-1 cells were treated as above and nuclei were
isolated after 12 h . The rate of transcription of the iNOS gene was deter-
mined as described in Materials and Methods . The following plasmid
DNA were used : piNOS, pGEM vector containing a 3.9-kbcDNA insert
ofmouse macrophage NOS ; p-actin, vector containing a chicken (3-actin
cDNA insert; pGEM, vector lacking any cDNA insert. Data shown are
from one representative experiment.plus picolinic acid or IFN-y plus hypoxia. The iNOS-HRE
is sufficient to drive the activation of a heterologous pro-
moter following stimulation with picolinic acid or hypoxia
alone. These data establish that a sequence homologous to a
hypoxia-inducible enhancer regulates the iNOS promoter
activity in murine macrophages and provide the first evi-
dence of the existence of a regulatory element responsive
to picolinic acid and of an inverse relationship between ox-
ygen levels and iNOS expression.
We have previously reported that the simultaneous stim-
ulation of ANA-1 macrophages with IFN-y plus picolinic
acid caused a major induction of iNOS transcription and
iNOS mRNA expression (31) . These data are in agreement
with the results of the transient transfection assays demon-
strating that picolinic acid acted synergistically with IFN-y
in inducing the expression of the full-length iNOS pro-
moter. Deletion of the iNOS promoter fragment contain-
ing an IFN-y-responsive element abolished the coopera-
tive interaction between IFN-y and picolinic acid in the
activation of iNOS promoter, which is in agreement with
the requirement for IFN-y to achieve maximal induction
of iNOS transcription (5, 7, 8). Although picolinic acid
alone did not induce detectable iNOS transcription, as as-
sessed by nuclear run-on analysis (31), we found that pi-
colinic acid alone induced low but consistent levels of ex-
pression of the iNOS promoter in transient transfection
assays. This discrepancy might be explained by negative
regulatory regions that control the expression of the en-
dogenous iNOS gene or by differences in the sensitivity of
the assays. A discrepancy between the extent of iNOS
mRNA expression and the induction of transfected iNOS
promoter-luciferase constructs by LPS was also observed in
the RAW 264 .7 macrophage cell line (8) .
Deletion and site-directed mutagenesis experiments dem-
onstrated that a 19 nt element containing a sequence ho-
mology to a HRE was required for the transcriptional acti-
vation ofthe iNOS promoter by IFN-'Y plus picolinic acid.
The HR-E, originally identified in the 50 nt enhancer ele-
ment of the 3' flanking region of the Epo gene (38), is
highly conserved between human and mouse (42) and me-
diates hypoxia-inducible gene transcription in Epo produc-
ing cells (38) . The hypoxia-inducible enhancer activity is
also present in non-Epo producing cell lines, suggesting a
general involvement of the HRE in the hypoxia-inducible
gene expression (40, 41) . The homology between the iNOS
promoter and the HRE comprised the consensus sequence
(5'-TACGTGCT-3') for the binding of a novel trans-acti-
vating factor (HIF-1) induced by stimulation of cells in low
oxygen tension (38, 43) . Deletion or mutation ofthe puta-
tive binding site of HIF-1 present in the iNOS-HRE con-
sistently decreased CAT activity induced by picolinic acid
in IFN-y-treated ANA-1 macrophages, demonstrating the
functional role of the iNOS-HRE in the activation ofiNOS
promoter. Activation of the iNOS-HRE by picolinic acid
was associated with a specific DNA-binding activity. Two
different complexes were observed in ANA-1 macrophages:
the first, constitutively present, was almost completely com-
peted by excess cold probe but not by unrelated oligonu-
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cleotide, suggesting that it was largely specific; the second
complex was inducible by picolinic acid and was inhibited
by excess specific probe. The binding pattern that we have
observed in murine macrophages is strikingly similar to that
reported in other cell types for HIF-1 transcription factor.
HIF-1 binding activity has been originally described in nu-
clear extracts from hypoxia-treated Hep3B cells using as
probe an 18-bp oligomer of the HRE present in the Epo
gene (38, 43). Our results strongly suggest that HIF-1 or a
closely related nuclear factor binds to the HIF-1 consensus
sequence of the iNOS promoter. However, the biochemi-
cal characterization of the nuclear factor induced by pi-
colinic acid in ANA-1 macrophages requires additional
studies.
The presence of a functional HRE in the iNOS pro-
moter suggested that hypoxia was a stimulus for its tran-
scriptional activation. Indeed, we found that hypoxia con-
sistently induced iNOS promoter activity in cooperation
with IFN-y. The iNOS-HRE was the target of hypoxia
because deletion or mutation of the iNOS-HRE almost
completely abrogated the cooperative interaction between
hypoxia and IFN-y. These data provided the first indica-
tion that iNOS could be a hypoxia-responsive gene. This
hypothesis was supported by the finding that hypoxia
caused a major increase of iNOS transcription and mRNA
expression in IFN-y-treated ANA-1 macrophages. So far,
hypoxia responsive sequences have been demonstrated to
play a functional role only in the hypoxia-inducible tran-
scriptional activation of genes encoding Epo (38, 42, 44)
and glycolytic enzymes (45, 46), whose functions are to
counteract the adverse effects of decreased oxygen levels .
Our data demonstrating that a hypoxia-inducible enhancer
controls iNOS transcriptional activity suggest that iNOS
might be the prototype ofa different class of oxygen-sensi-
tive genes.
The studies of the functional activity of the iNOS-HRE
in the context of a heterologous promoter established that
this sequence responded to picolinic acid or to hypoxia
alone. Three copies of the wild-type iNOS-HRE inserted
5' to a tk promoter-CAT reporter gene mediated picolinic
acid- or hypoxia- but not IFN-y- or LPS-inducibility in
ANA-1 macrophages, indicating that either picolinic acid
or hypoxia can independently activate the iNOS-HRE .
These results are consistent with the possibility that the
synergistic activation of the iNOS promoter by IFN-y and
picolinic acid or hypoxia may be achieved through stimula-
tion of interferon regulatory factor binding site (IRF-E)
and iNOS-HRE, respectively, suggesting a cooperative in-
teraction between hypoxia- and IFN-y-regulated sequences.
A three-bp mutation of the HIF-1-binding site abolished
the constitutive activity of the iNOS-HRE and eliminated
the picolinic acid- or the hypoxia-inducibility, indicating
that the integrity of the consensus sequence for the binding
of HIF-1 was required for the functional activity of the
iNOS-HRE . In agreement with these results, the same
mutation was shown to inhibit the HIF-1 binding and
eliminate the hypoxia-inducible enhancer activity ofthe el-
ement present in the Epo gene (38, 41, 43).
Activation of iNOS Promoter by Picolinic Acid or HypoxiaTwo regulatory sequences have been identified so far in
the 5'-flanking region of the iNOS gene and they are in-
volved in the activation of iNOS transcription induced by
IFN-y plus LPS. An upstream region (from -923 to -913),
containing an IRF-E, binds IRF-1 and is required for the
synergistic enhancement of iNOS expression by IFN-y, as
demonstrated in vivo in IRF-1 knock-out mice (9), and in
vitro by functional studies with the murine macrophage-
like cell line RAW 264.7 (10) . A downstream region con-
taining a NF-KB consensus sequence (at position -85 to
-76) is necessary for LPS inducibility of the iNOS pro-
moter (11). The pathway of iNOS transcriptional activa-
tion induced by IFN-y plus LPS is particularly relevant for
NO production during the course of microbial infections.
However, the pleiotropic expression ofiNOS and the com-
plex structure of its promoter suggest that different signals
and multiple regulatory elements control iNOS transcrip-
tion. The finding that picolinic acid or hypoxia induce
iNOS transcription through a novel regulatory sequence
provides evidence of the existence of a distinct pathway of
iNOS transcriptional activation that may be important dur-
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